Metagenomics-Guided Personalized Synbiotic Protocol in Children with ASD: An Exploratory Case Series
Seven children with ASD received individualized metagenomics-guided synbiotics, with caregiver-reported improvements in gastrointestinal symptoms and selected behavioral domains in a subset of participants.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The abstract reports that several participants showed improvements in gastrointestinal symptoms and selected behavioral domains. In a subset, gastrointestinal improvements preceded measurable behavioral changes. Findings are explicitly described as exploratory and not causally interpretable.
How it was done
Seven children (aged 5–12) with ASD underwent longitudinal fecal shotgun metagenomic profiling; individualized synbiotic formulations were iteratively refined using the SMART framework. Gastrointestinal outcomes relied on caregiver reports; behavior was assessed with standardized instruments.
Risk of bias
N=7, no control group, unblinded caregiver-reported gastrointestinal outcomes — limitations explicitly acknowledged in the abstract. Case series design precludes causal inference or generalization.
What this study does NOT prove
The study does not prove that metagenomics-guided personalized synbiotics improve ASD symptoms or that microbiome modulation causes behavioral change.
In clinical practice
Evidence is insufficient to inform clinical practice changes. The study functions solely as hypothesis generation for future controlled trials.
Limitations
N=7, no control group, unblinded caregiver-reported gastrointestinal outcomes — limitations explicitly acknowledged in the abstract. Case series design precludes causal inference or generalization.
Technical appendix
Version history
- 1.0 · 2026-09-01 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.